Lakefront Biotherapeutics (GLPGF) Cash from Operations Growth (5y) (2020 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Cash from Operations Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 7.90% |
| Dec 31, 2025 | 35.87% |
| Mar 31, 2025 | 11.79% |
| Dec 31, 2024 | 13.76% |
| Mar 31, 2024 | -10.29% |
| Dec 31, 2023 | -21.85% |
| Mar 31, 2023 | -15.80% |
| Dec 31, 2022 | -24.15% |
| Mar 31, 2022 | -23.37% |
| Jun 30, 2021 | -32.52% |
| Mar 31, 2021 | -20.37% |
| Dec 31, 2020 | -32.32% |